PH12023551406A1 - Chemical compounds useful for inhibiting nav1 .8 voltage-gated sodium channels and treating nav1 .8 mediated diseases - Google Patents
Chemical compounds useful for inhibiting nav1 .8 voltage-gated sodium channels and treating nav1 .8 mediated diseasesInfo
- Publication number
- PH12023551406A1 PH12023551406A1 PH1/2023/551406A PH12023551406A PH12023551406A1 PH 12023551406 A1 PH12023551406 A1 PH 12023551406A1 PH 12023551406 A PH12023551406 A PH 12023551406A PH 12023551406 A1 PH12023551406 A1 PH 12023551406A1
- Authority
- PH
- Philippines
- Prior art keywords
- nav1
- inhibiting
- treating
- voltage
- sodium channels
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 108010056565 NAV1.8 Voltage-Gated Sodium Channel Proteins 0.000 title abstract 2
- 102000004194 NAV1.8 Voltage-Gated Sodium Channel Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 | |
| PCT/EP2021/086101 WO2022129283A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12023551406A1 true PH12023551406A1 (en) | 2024-01-22 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2023/551406A PH12023551406A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1 .8 voltage-gated sodium channels and treating nav1 .8 mediated diseases |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4262978A1 (enExample) |
| JP (1) | JP2024502231A (enExample) |
| KR (1) | KR20230121827A (enExample) |
| CN (1) | CN116710463A (enExample) |
| AU (1) | AU2021403606B2 (enExample) |
| CA (1) | CA3202328A1 (enExample) |
| CL (1) | CL2023001750A1 (enExample) |
| CO (1) | CO2023008049A2 (enExample) |
| IL (1) | IL303795A (enExample) |
| MX (1) | MX2023007244A (enExample) |
| PH (1) | PH12023551406A1 (enExample) |
| SA (1) | SA523441263B1 (enExample) |
| WO (1) | WO2022129283A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604477SA (en) * | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| KR102714561B1 (ko) * | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| MA56398A (fr) * | 2019-06-27 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 |
-
2021
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en not_active Ceased
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko active Pending
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja not_active Ceased
- 2021-12-16 PH PH1/2023/551406A patent/PH12023551406A1/en unknown
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en not_active Withdrawn
- 2021-12-16 AU AU2021403606A patent/AU2021403606B2/en active Active
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-18 SA SA523441263A patent/SA523441263B1/ar unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3202328A1 (en) | 2022-06-23 |
| IL303795A (en) | 2023-08-01 |
| JP2024502231A (ja) | 2024-01-18 |
| SA523441263B1 (ar) | 2025-01-07 |
| AU2021403606B2 (en) | 2024-11-14 |
| MX2023007244A (es) | 2023-06-29 |
| CO2023008049A2 (es) | 2023-06-30 |
| CL2023001750A1 (es) | 2024-01-19 |
| WO2022129283A1 (en) | 2022-06-23 |
| KR20230121827A (ko) | 2023-08-21 |
| AU2021403606A1 (en) | 2023-06-22 |
| CN116710463A (zh) | 2023-09-05 |
| EP4262978A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014942A (es) | Nuevos compuestos. | |
| MX2022013637A (es) | Nuevos compuestos de triazinoindol. | |
| MX2022013323A (es) | Compuestos triciclicos como inhibidores de nlrp3. | |
| AR002267A1 (es) | Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion. | |
| CY1109906T1 (el) | Παραγωγα c3-kyano εποθιλονης | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| PH12021553248A1 (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| MX2025010552A (es) | Inhibidores de la dna polimerasa theta | |
| MX2023003459A (es) | Nuevos compuestos. | |
| GEAP202516637A (en) | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain | |
| EP4223289C0 (en) | MEDICINAL PRODUCT COMPRISING THE ADRB2 INHIBITOR ICI 118551 FOR THE TREATMENT OF PSORIASIS | |
| WO2024243304A3 (en) | Bicyclic heteroaryl compounds | |
| MX2026001837A (es) | Compuestos que contienen ciclobutilo | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| WO2024020534A3 (en) | Cyclic compounds and methods of using same | |
| TNSN05238A1 (fr) | Derives du benzenesulfonamide, leur procede de preparation et leur utilisation pour le traitement de la douleur | |
| WO2023102162A8 (en) | Novel hdac inhibitors and therapeutic use thereof | |
| MX2023003458A (es) | Nuevos compuestos. | |
| BR0308837A (pt) | Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i) | |
| MX2023007244A (es) | Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8. | |
| WO2023205595A3 (en) | Egfr inhibitors in cancer treatment | |
| MX2025006291A (es) | Metodos de tratamiento de trastornos neurologicos | |
| EP4631573A3 (en) | Tead inhibitors | |
| MX2024013886A (es) | Derivados de pirrolidinona como inhibidores de la cinasa inductora de nf-kb | |
| WO2023130054A3 (en) | Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof |